Drugs / Capvaxvie
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06829238 | Apr 2025 → Nov 2028 expected | HIV infectious disease, autoinflammatory syndrome, immune dysregulation, autoimmunity, and autoinflammation | University of Alabama at Birmingham | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Capvaxvie | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06829238 ↗ |
| Known as | PCV21 | “All participants will take a Capvaxvie (PCV21, pneumococcal) vaccine.” NCT06829238 ↗ |
| Modality | Vaccine | “All participants will take a Capvaxvie (PCV21, pneumococcal) vaccine.” NCT06829238 ↗ |